Search

for
Search:

Research

5 / 1000+ results

research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

2 citations , February 2023 in “F&S Reports”

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

research Adenosine stimulates growth of dermal papilla and lengthens the anagen phase by increasing the cysteine level via fibroblast growth factors 2 and 7 in an organ culture of mouse vibrissae hair follicles

28 citations , October 2011 in “International Journal of Molecular Medicine”

In this study, adenosine was found to stimulate hair follicle growth in vitro by promoting growth factor expression, β-catenin activation, and downstream signaling pathways.

research Expression of Cyclooxygenase Isozymes During Morphogenesis and Cycling of Pelage Hair Follicles in Mouse Skin: Precocious Onset of the First Catagen Phase and Alopecia upon Cyclooxygenase-2 Overexpression

41 citations , September 2003 in “Journal of Investigative Dermatology”

This study suggests that the COX-2 enzyme plays a role in hair follicle biology, as transgenic overexpression in mice induced hair follicle cycling disturbances and alopecia, which was mitigated by COX-2 inhibition.

research Final Phase in the Validation of the Cross-Cultural Adaptation of the Hair-Specific Skindex-29 Questionnaire Into Spanish: Sensitivity to Change and Correlation With the 12-Item Short-Form Health Survey

1 citations , November 2019 in “Actas Dermo-Sifiliográficas”

This study found that the Spanish version of the hair-specific Skindex-29 questionnaire effectively detected changes in health-related quality of life among women with female-pattern hair loss, and the scores were significantly correlated with the SF-12 survey results after treatment with a 5 alpha-reductase inhibitor.

research A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

View more "phase 2" in research →

Community Join

5 / 1000+ results

community Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)

5 months ago

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

community VDPHL01 phase-2/3 results comparison

in Research/Science 128 upvotes 5 months ago

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

View more "phase 2" in community →

Learn

8 / 27 results

learn Hair Transplant

What happens after a hair transplant? Expect mild swelling and redness, with new hair growth starting in 3 to 6 months.
How long does a hair transplant procedure take? A hair transplant procedure typically takes 4 to 8 hours.

learn Scalp Micropigmentation

How long does Scalp Micropigmentation last, and does it need touch-ups over time? Providers say SMP usually needs a touch-up every 1 to 5 years. It fades but does not fully disappear, and removal needs laser treatment that may be incomplete.

learn TDM-105795

What should consumers know about the current development stage and availability of TDM-105795 in hair loss products? TDM-105795 is an experimental topical drug that has completed one 16-week Phase 2 trial in 71 men. It is not approved and is not available in any approved hair-loss product.
What types of alopecia or hair loss conditions might TDM-105795 be designed to target based on current research? TDM-105795 has been studied only in men with androgenetic alopecia, in two Phase 1 studies and one 16-week Phase 2 trial. There is no research on it in women or in any other type of hair loss.